Abiopharma

🔍 Whitaker Anne Clem (Director)

Company: ICON PLC (ICLR)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 1,732 shares of Ordinary Shares (Direct)
  Date: 2026-08-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,732.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 88 shares of Ordinary Shares at $162.72 per share (Direct)
  Date: 2026-08-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,644.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 96 shares of Ordinary Shares at $163.77 per share (Direct)
  Date: 2026-08-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,548.00 | transaction_form_type: 4 | Footnotes: F3, F5
• Sold 590 shares of Ordinary Shares at $164.47 per share (Direct)
  Date: 2026-08-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 958.00 | transaction_form_type: 4 | Footnotes: F3, F6
• Sold 67 shares of Ordinary Shares at $165.51 per share (Direct)
  Date: 2026-08-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 891.00 | transaction_form_type: 4 | Footnotes: F3, F7
• Sold 1,732 shares of Restricted Share Units (Derivative)
  Date: 2026-08-10 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F1, F1
• Acquired 1,324 shares of Restricted Share Units (Derivative)
  Date: 2026-08-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,324.00 | transaction_form_type: 4 | Footnotes: F2, F8, F8, F8

Footnotes:

• F1: These restricted share units were granted on May 22, 2025 and vested on August 10, 2026.
• F2: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting.
• F3: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $162.08 to $163.0799, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $163.15 to $164.1499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $164.16 to $165.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
• F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $165.16 to $166.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
• F8: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027.
• REMARKS: Due to the issuer's status as a foreign private issuer pursuant to Rule 3a12-3(b) under the Securities Exchange Act of 1934 (the "Act"), the reporting person's transactions in the issuer's equity securities are exempt from Sections 16(b) and 16(c) of the Act.